The Artificial Tears Market, estimated to be valued at USD 3.74 Billion in 2025, is projected to exhibit a CAGR of 6.1%, reaching USD 5.66 Billion by 2032.

Growth is being driven by the increasing prevalence of dry eye syndrome, rising screen time from digital device usage, and the growing elderly population worldwide. Advancements in formulations such as preservative-free solutions, lipid-based drops, and long-lasting hydration therapies are further boosting adoption among patients. Supportive healthcare initiatives, greater availability of over-the-counter (OTC) eye care products, and rising awareness regarding ocular health are fueling the market expansion.

Additionally, the integration of novel drug delivery systems, such as nanotechnology-based carriers and sustained-release formulations, is enhancing treatment efficacy and patient compliance. The increasing burden of eye disorders associated with urban lifestyles, coupled with expanding access to ophthalmic care in emerging markets, is expected to create substantial opportunities for the artificial tears market over the forecast period.

Market Takeaways

• By Type, Polyethylene Glycols (PEG) and Polypropylene Glycols (PPG) are expected to dominate the artificial tears market with a 43.7% share in 2025, driven by their proven efficacy in lubricating the ocular surface and widespread use in dry eye treatment formulations.
• By Delivery, Eye Drops are projected to hold the largest share of 67.8% in 2025, supported by their convenience, rapid relief, and higher patient compliance compared to ointments.
• By Packaging, Single-use Vials are anticipated to witness strong growth due to increasing consumer preference for preservative-free solutions and the reduced risk of contamination, especially among patients with sensitive eyes or chronic conditions.
• By Application, Dry Eye Syndrome is expected to remain the leading segment, driven by the rising incidence of lifestyle-induced dry eye disease, higher digital screen exposure, and growing awareness of ocular health.
• By Distribution Channel, Drug Stores & Retail Pharmacies are projected to capture a major share, supported by easy accessibility, growing OTC availability, and consumer preference for quick, walk-in purchases. Online Pharmacies are also expected to witness rapid growth, fueled by increasing e-commerce penetration and convenience-driven purchasing patterns.
• Regionally, North America is set to lead the artificial tears market, supported by a high prevalence of dry eye cases, strong healthcare infrastructure, and greater adoption of advanced formulations.

Artificial Tears Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/artificial-tears-market

Market Dynamics

The artificial tears market is experiencing steady growth, driven by the rising prevalence of dry eye syndrome, increasing screen exposure from digital devices, and a growing elderly population susceptible to ocular disorders. Greater awareness of eye health, coupled with expanding access to over-the-counter (OTC) ophthalmic products, is fueling widespread adoption across both developed and emerging markets. Advancements in preservative-free formulations, lipid-based drops, and sustained-release therapies are further enhancing efficacy and patient compliance.

A key growth driver is the surge in cases of lifestyle-related eye strain caused by prolonged digital screen use, urban pollution, and reduced blink rates. The expanding distribution of artificial tears through hospital pharmacies, retail pharmacies, and rapidly growing online channels is improving accessibility and convenience for consumers. Additionally, increasing investments in ophthalmic research and the integration of novel drug delivery technologies, such as nanocarriers and hydrogel-based systems, are enhancing product innovation and market competitiveness.

However, the market faces challenges such as the availability of cheaper generic substitutes, patient skepticism regarding long-term dependency on artificial tears, and potential side effects linked to preservatives in certain formulations. Pricing pressures and limited reimbursement policies in some regions may also restrict adoption.

Despite these hurdles, the long-term outlook for the artificial tears market remains positive. Rising healthcare expenditure, growing ophthalmology infrastructure in emerging economies, and continuous R&D focused on advanced and natural-based formulations are expected to unlock significant opportunities, positioning artificial tears as an essential solution in the global eye care industry over the forecast period.

Market Trends

• Shift Toward Preservative-Free Formulations

Growing concerns over long-term side effects of preservatives, such as ocular surface irritation and toxicity, are accelerating the demand for preservative-free artificial tears. Manufacturers are introducing single-use vials and advanced multi-dose systems designed to maintain sterility without chemical preservatives, enhancing safety for chronic dry eye patients.

In January 2022, Alcon unveiled Systane Complete Preservative-Free Lubricant Eye Drops in Europe—a multi-dose bottle powered by PureFlow technology that keeps the solution sterile without chemical preservatives. This launch marked Alcon's expansion into the rapidly growing preservative-free segment, which accounts for over 40 % of the global artificial tears category.

• Integration of Natural & Bio-Based Ingredients

There is an increasing trend toward artificial tears formulated with natural polymers, plant-based extracts, and biocompatible carriers to mimic natural tear composition. Products enriched with hyaluronic acid, lipids, or omega-3 fatty acids are gaining traction as patients and physicians seek safer, more holistic alternatives to synthetic-only formulations.

In November 2022, Optometry Times published that a new preservative-free artificial tear was released in the U.S., combining trehalose, hyaluronic acid, and povidone. This formula offers longer-lasting lubrication and cellular protection, particularly effective for contact lens wearers and patients with varying dry eye conditions.

Market Opportunities

• Expanding Telemedicine and Online Retail Channels

The rising adoption of telemedicine and e-commerce platforms is opening new distribution avenues for artificial tears. Online sales are growing at approximately 15% annually, with brands leveraging digital platforms to offer customized treatment plans, subscription models, and convenient direct-to-consumer delivery. Regions with increasing internet penetration—such as Africa and Southeast Asia—are particularly promising for the market expansion.

In July 2023, Jobson Research published a report indicating an increase in the adoption of telemedicine in eye care, particularly during the COVID-19 pandemic. The report highlighted the integration of telemedicine into contact lens care, providing insights into the current state of telemedicine usage and practitioner perspectives on its feasibility as a vision care tool.

• Untapped Geriatric and Screen-Exposed Populations

Demographic shifts and modern lifestyle habits are creating a substantial, yet underserved, market for artificial tears. The global population of individuals over 60 is rapidly increasing, and this age group naturally faces a higher incidence of dry eye symptoms due to age-related decline in tear production and ocular surface health. At the same time, widespread use of digital devices—including computers, smartphones, and tablets—is driving eye strain, leading to computer vision syndrome and exacerbating dry eye conditions in younger populations. Despite the growing need, penetration of artificial tears within these segments remains relatively low. This gap indicates a significant growth opportunity for manufacturers to develop targeted products and educational campaigns that cater specifically to older adults and heavy screen users, offering solutions that are tailored to their unique needs for ocular comfort, hydration, and eye health.

Analyst View

• The artificial tears market is set for steady growth through 2032, driven by the rising prevalence of dry eye syndrome, increasing digital screen usage, and a growing elderly population. Greater awareness of eye health, expanded access to over-the-counter (OTC) products, and supportive healthcare initiatives are further fueling adoption across developed and emerging markets.
• Demand is being propelled by both lifestyle- and age-related ocular disorders. Increased screen time, urban pollution, and reduced blink rates are driving the need for eye lubrication solutions, while geriatric populations require targeted formulations to manage age-related tear deficiency. Eye drops remain the leading delivery form due to convenience, rapid relief, and higher patient compliance, with single-use vials gaining popularity for preservative-free solutions.
• On the technology front, advancements in preservative-free, lipid-based, and long-lasting hydration formulations, as well as nanotechnology- and hydrogel-based drug delivery systems, are improving efficacy and patient adherence. Integration of natural and bio-based ingredients, such as hyaluronic acid, trehalose, and omega-3 fatty acids, is further enhancing safety and market differentiation.
• Regionally, North America is expected to lead the market, supported by high prevalence of dry eye cases, strong healthcare infrastructure, and adoption of advanced formulations. Asia Pacific and Latin America offer high-growth potential due to increasing healthcare access, urbanization, and rising awareness of eye health.
• From an investment perspective, key opportunities exist in telemedicine-enabled distribution, targeting geriatric and heavy-screen populations, and developing innovative preservative-free and natural-based formulations. Challenges include competition from generic products, pricing pressures, and potential safety concerns associated with preservatives. Strategic product innovation, regional expansion, and patient education are expected to sustain long-term growth in the artificial tears market.

Recent Key Developments

• In February 2025, Alcon announced the U.S. launch of SYSTANE PRO, a preservative-free eye drop designed to provide the longest-lasting relief yet. This product aims to revolutionize dry eye relief with its advanced formula.

Competitive Landscape

• Allergan (AbbVie Inc.)
• Alcon Inc.
• Bausch & Lomb
• Santen Pharmaceutical Co., Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Eyevance Pharmaceuticals LLC
• Johnson & Johnson
• Bayer AG
• Otsuka Pharmaceutical Co., Ltd.
• Similasan Corporation
• Akorn Operating Company LLC

Artificial Tears Market Segmentation

• By Type
• Polyethylene Glycols (PEG) and Polypropylene Glycols (PPG)
• Cellulose
• Others
• By Delivery
• Eye Drops
• Ointments
• By Packaging
• Single-use Vials
• Multi-use Bottles
• By Application
• Dry Eye Syndrome
• Allergies & Infections
• Others
• By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • France
  • Russia
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • Japan
  • China
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of the Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa